Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) Institutional Ownership

CUSIP: 74365A309

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
PLX on NYSE
Shares outstanding
80,165,500
Price per share
$3.14
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
14,904,284
Total reported value
$26,832,150
% of total 13F portfolios
0%
Share change
+1,045,520
Value change
+$1,854,272
Number of holders
82
Price from insider filings
$3.14
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Investment Quick Answers

What is CUSIP 74365A309?
CUSIP 74365A309 identifies PLX - Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAK Capital Fund LP 5.8% $13,576,829 4,649,599 MAK Capital Fund LP 26 Feb 2026

As of 31 Dec 2025, 82 institutional investors reported holding 14,904,284 shares of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX). This represents 19% of the company’s total 80,165,500 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) together control 17% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 4.5% 3,647,106 +2.7% 0% $6,564,791
Opaleye Management Inc. 3.1% 2,478,176 -4% 0.59% $4,460,717
RENAISSANCE TECHNOLOGIES LLC 1.6% 1,263,300 -4% 0% $2,273,940
NORTHERN TRUST CORP 1.1% 865,708 -4.1% 0% $1,558,274
GEODE CAPITAL MANAGEMENT, LLC 1% 830,054 +1.3% 0% $1,494,096
STATE STREET CORP 0.73% 585,261 +17% 0% $1,053,470
Stratos Wealth Partners, LTD. 0.62% 500,000 0% 0.01% $900,000
VANGUARD GROUP INC 0.61% 488,552 +5.2% 0% $879,393
CITADEL ADVISORS LLC 0.4% 317,628 +751% 0% $571,730
JANE STREET GROUP, LLC 0.36% 289,917 0% $521,851
GOLDMAN SACHS GROUP INC 0.33% 262,809 +74% 0% $473,056
UBS Group AG 0.33% 262,520 +38% 0% $472,536
Connor, Clark & Lunn Investment Management Ltd. 0.29% 232,093 -42% 0% $417,767
Main Street Financial Solutions, LLC 0.27% 214,100 +66% 0.03% $385,380
Bank of New York Mellon Corp 0.26% 210,867 +52% 0% $379,561
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.24% 189,100 0% 0.01% $340,380
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.22% 175,070 0% 0% $315,126
COMMONWEALTH EQUITY SERVICES, LLC 0.21% 171,772 0% 0% $309,190
EVERGREEN CAPITAL MANAGEMENT LLC 0.21% 171,338 0% 0.01% $308,409
Round Rock Advisors LLC 0.19% 155,102 0.04% $279,184
Diametric Capital, LP 0.17% 138,929 -23% 0.07% $250,072
MORGAN STANLEY 0.16% 131,987 +86% 0% $237,576
BARCLAYS PLC 0.14% 112,849 +11% 0% $203,129
Nuveen, LLC 0.11% 90,188 0% 0% $162,338
WELLS FARGO & COMPANY/MN 0.1% 79,002 +84% 0% $142,204

Institutional Holders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 14,904,284 $26,832,150 +$1,854,272 $1.80 82
2025 Q3 13,927,352 $30,914,125 +$4,618,112 $2.22 76
2025 Q2 11,908,531 $17,628,861 +$1,905,095 $1.48 62
2025 Q1 8,186,092 $20,953,817 +$9,615,818 $2.56 63
2024 Q4 4,467,337 $8,398,680 +$2,201,784 $1.88 46
2024 Q3 3,383,529 $3,451,053 -$2,253,845 $1.02 43
2024 Q2 5,625,789 $6,582,396 -$4,774,740 $1.17 64
2024 Q1 9,445,037 $11,900,614 -$696,249 $1.26 61
2023 Q4 9,848,515 $17,531,878 +$1,241,481 $1.78 65
2023 Q3 9,166,276 $15,209,597 -$97,896 $1.66 61
2023 Q2 8,974,519 $17,902,094 +$11,998,091 $2.00 66
2023 Q1 2,937,638 $6,146,705 +$447,739 $2.10 34
2022 Q4 3,567,822 $4,870,646 +$111,553 $1.37 26
2022 Q3 3,548,189 $3,696,081 +$2,398,630 $1.04 26
2022 Q2 1,193,025 $1,298,298 +$25,721 $1.09 27
2022 Q1 1,217,014 $1,287,936 -$1,765,451 $1.06 28
2021 Q4 2,921,778 $2,436,675 -$1,654,962 $0.83 24
2021 Q3 4,412,957 $5,908,463 +$92,750 $1.33 32
2021 Q2 4,315,299 $8,240,101 -$19,328,651 $1.91 31
2021 Q1 8,821,889 $39,349,366 +$21,195,496 $4.46 36
2020 Q4 4,087,703 $14,838,993 -$3,209,332 $3.63 22
2020 Q3 4,761,719 $18,443,257 -$1,925,407 $3.87 23
2020 Q2 5,260,461 $19,818,169 -$2,815,871 $3.79 26
2020 Q1 5,996,154 $14,097,585 +$12,574,926 $2.35 14
2019 Q4 645,294 $2,114,608 +$2,114,608 $3.28 8